News

The FDA approval allows Isturisa to treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still suffering from the

BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases. The company expects to report data from the proof of

The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2020. In addition, the FDA has communicated that they are not

NASH, a progressive disease of the liver, commences with fat accumulation in the liver and may lead to cirrhosis and liver failure. Saroglitazar is claimed to be the

Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River, Venrock,

Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum, the predominant cause of the most

The company will inform the members of the US Congress regarding the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) for the treatment of high-risk individuals with COVID-19.

As part of the collaboration, the AI-driven generative modelling technology of Iktos will be combined with SynFini, a fully automated end-to-end synthetic chemistry system developed by SRI. The

The Series B financing was led by Pivotal bioVenture Partners, with participation from new investors Cormorant Asset Management, Cowen Healthcare Investments, EcoR1 Capital, Fidelity Management & Research Company,